Facebook-f Linkedin Twitter

CONFERENCE COVERAGE: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  1. 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel)
  2. Adding Pembrolizumab to Chemotherapy Improves Survival in People With Advanced Cervical Cancer 
  3. AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers
  4. Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors 
  5. Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101
  6. AstraZeneca to highlight momentum of cancer medicines across its pipeline
  7. Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in R/R CLL
  8. Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer
  9. Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline 
  10. EMD Serono Highlights Commitment to Improving Cancer Outcomes 
  11. Fianlimab Combined with Libtayo Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
  12. Genmab Announces Multiple Abstracts to be Presented
  13. Gilead And Kite Oncology To Showcase Advances Across The Pipeline Aiming To Address Unmet Needs In Cancer Care 
  14. Immutep Announces Publication of Abstracts 
  15. Karyopharm to Present New Selinexor Data 
  16. KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced Renal Cell Carcinoma
  17. Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma
  18. Merck to Present New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology
  19. Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402
  20. Takeda to Present Oncology Portfolio and Pipeline Data

Stay up-to-date with our biotech and Onco News

Facebook Linkedin Twitter

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.

Facebook Linkedin Twitter

Onco-This-Week

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.